Created by potrace 1.16, written by Peter Selinger 2001-2019beatandraise.com

ELI LILLY & Co

Statements

Graphics

g120317g32y59.jpgg120317g91z99.jpg
NotesSupport
aboutterms
2.2.0.25truefalse41504 - Disclosure - Contingencies (Details)truefalseIn Millions, unless otherwise specifiedfalse1falsefalsefalsefalse7/1/2008 - 12/31/2008 Duration_7_1_2008_To_12_31_2008http://www.sec.gov/CIK0000059478duration2008-07-01T00:00:002008-12-31T00:00:00Unit14Standardhttp://www.xbrl.org/2003/instancepurexbrli02falsefalseUSDfalsefalse1/1/2010 - 12/31/2010 USD ($) USD ($) / shares $Duration_1_1_2010_To_12_31_2010http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-12-31T00:00:00Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit15Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit1Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit14Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2009 - 12/31/2009 USD ($) USD ($) / shares $Duration_1_1_2009_To_12_31_2009http://www.sec.gov/CIK0000059478duration2009-01-01T00:00:002009-12-31T00:00:00Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit1Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit15Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit14Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$4falsefalseUSDfalsefalse1/1/2008 - 12/31/2008 USD ($) USD ($) / shares $Duration_1_1_2008_To_12_31_2008http://www.sec.gov/CIK0000059478duration2008-01-01T00:00:002008-12-31T00:00:00Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit1Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit14Standardhttp://www.xbrl.org/2003/instancepurexbrli0Unit15Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$5falsefalseUSDtruefalse{us-gaap_LossContingenciesByNatureOfContingencyAxis} : Product Liability Litigation [Member] {us-gaap_ProductOrServiceAxis} : Zyprexa [Member] 10/1/2007 - 12/31/2007 USD ($) $Duration_10_1_2007_To_12_31_2007http://www.sec.gov/CIK0000059478duration2007-10-01T00:00:002007-12-31T00:00:00falsefalseProduct Liability Litigation [Member]us-gaap_LossContingenciesByNatureOfContingencyAxisxbrldihttp://xbrl.org/2006/xbrldilly_ProductLiabilityLitigationMemberus-gaap_LossContingenciesByNatureOfContingencyAxisexplicitMemberfalsefalseZyprexa [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ZyprexaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit14Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$6falsefalseUSDtruefalse{us-gaap_LossContingenciesByNatureOfContingencyAxis} : Product Liability Litigation [Member] {us-gaap_ProductOrServiceAxis} : Zyprexa [Member] 4/1/2005 - 6/30/2005 USD ($) $Duration_4_1_2005_To_6_30_2005http://www.sec.gov/CIK0000059478duration2005-04-01T00:00:002005-06-30T00:00:00falsefalseProduct Liability Litigation [Member]us-gaap_LossContingenciesByNatureOfContingencyAxisxbrldihttp://xbrl.org/2006/xbrldilly_ProductLiabilityLitigationMemberus-gaap_LossContingenciesByNatureOfContingencyAxisexplicitMemberfalsefalseZyprexa [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ZyprexaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit14Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$7falsefalsetruefalse{us-gaap_LossContingenciesByNatureOfContingencyAxis} : Product Liability Litigation [Member] {us-gaap_ProductOrServiceAxis} : Zyprexa [Member] 1/1/2010 - 12/31/2010 Duration_1_1_2010_To_12_31_201016http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseProduct Liability Litigation [Member]us-gaap_LossContingenciesByNatureOfContingencyAxisxbrldihttp://xbrl.org/2006/xbrldilly_ProductLiabilityLitigationMemberus-gaap_LossContingenciesByNatureOfContingencyAxisexplicitMemberfalsefalseZyprexa [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ZyprexaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit14Standardhttp://www.xbrl.org/2003/instancepurexbrli08falsefalsetruefalse{us-gaap_LossContingenciesByNatureOfContingencyAxis} : Product Liability Litigation [Member] {us-gaap_ProductOrServiceAxis} : Zyprexa [Member] 4/1/2005 - 12/31/2010 Duration_4_1_2005_To_12_31_2010http://www.sec.gov/CIK0000059478duration2005-04-01T00:00:002010-12-31T00:00:00falsefalseProduct Liability Litigation [Member]us-gaap_LossContingenciesByNatureOfContingencyAxisxbrldihttp://xbrl.org/2006/xbrldilly_ProductLiabilityLitigationMemberus-gaap_LossContingenciesByNatureOfContingencyAxisexplicitMemberfalsefalseZyprexa [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ZyprexaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit14Standardhttp://www.xbrl.org/2003/instancepurexbrli09falsefalsetruefalse{us-gaap_LossContingenciesByNatureOfContingencyAxis} : Multi District Litigation MDL [Member] {us-gaap_ProductOrServiceAxis} : Zyprexa [Member] 1/1/2010 - 12/31/2010 Duration_1_1_2010_To_12_31_201015http://www.sec.gov/CIK0000059478duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseMulti District Litigation MDL [Member]us-gaap_LossContingenciesByNatureOfContingencyAxisxbrldihttp://xbrl.org/2006/xbrldilly_MultiDistrictLitigationMdlMemberus-gaap_LossContingenciesByNatureOfContingencyAxisexplicitMemberfalsefalseZyprexa [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ZyprexaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit14Standardhttp://www.xbrl.org/2003/instancepurexbrli010falsefalseUSDtruefalse{us-gaap_LossContingenciesByNatureOfContingencyAxis} : Marketing and Promotional Practices [Member] {us-gaap_ProductOrServiceAxis} : Zyprexa [Member] 1/1/2009 - 3/31/2009 USD ($) $Duration_1_1_2009_To_3_31_2009http://www.sec.gov/CIK0000059478duration2009-01-01T00:00:002009-03-31T00:00:00falsefalseMarketing and Promotional Practices [Member]us-gaap_LossContingenciesByNatureOfContingencyAxisxbrldihttp://xbrl.org/2006/xbrldilly_MarketingAndPromotionalPracticesMemberus-gaap_LossContingenciesByNatureOfContingencyAxisexplicitMemberfalsefalseZyprexa [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ZyprexaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit14Standardhttp://www.xbrl.org/2003/instancepurexbrli0Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11falsefalseUSDtruefalse{us-gaap_LossContingenciesByNatureOfContingencyAxis} : Marketing and Promotional Practices [Member] {us-gaap_ProductOrServiceAxis} : Zyprexa [Member] 10/1/2008 - 12/31/2008 USD ($) $Duration_10_1_2008_To_12_31_20083http://www.sec.gov/CIK0000059478duration2008-10-01T00:00:002008-12-31T00:00:00falsefalseMarketing and Promotional Practices [Member]us-gaap_LossContingenciesByNatureOfContingencyAxisxbrldihttp://xbrl.org/2006/xbrldilly_MarketingAndPromotionalPracticesMemberus-gaap_LossContingenciesByNatureOfContingencyAxisexplicitMemberfalsefalseZyprexa [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ZyprexaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit14Standardhttp://www.xbrl.org/2003/instancepurexbrli0Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$12falsefalsetruefalse{us-gaap_LossContingenciesByNatureOfContingencyAxis} : Marketing and Promotional Practices [Member] {us-gaap_ProductOrServiceAxis} : Zyprexa [Member] 7/1/2008 - 9/30/2008 Duration_7_1_2008_To_9_30_2008http://www.sec.gov/CIK0000059478duration2008-07-01T00:00:002008-09-30T00:00:00falsefalseMarketing and Promotional Practices [Member]us-gaap_LossContingenciesByNatureOfContingencyAxisxbrldihttp://xbrl.org/2006/xbrldilly_MarketingAndPromotionalPracticesMemberus-gaap_LossContingenciesByNatureOfContingencyAxisexplicitMemberfalsefalseZyprexa [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ZyprexaMemberus-gaap_ProductOrServiceAxisexplicitMember13falsefalseUSDtruefalse{us-gaap_LossContingenciesByNatureOfContingencyAxis} : Marketing and Promotional Practices [Member] {us-gaap_ProductOrServiceAxis} : Zyprexa [Member] 1/1/2008 - 3/31/2008 USD ($) $Duration_1_1_2008_To_3_31_20082http://www.sec.gov/CIK0000059478duration2008-01-01T00:00:002008-03-31T00:00:00falsefalseMarketing and Promotional Practices [Member]us-gaap_LossContingenciesByNatureOfContingencyAxisxbrldihttp://xbrl.org/2006/xbrldilly_MarketingAndPromotionalPracticesMemberus-gaap_LossContingenciesByNatureOfContingencyAxisexplicitMemberfalsefalseZyprexa [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ZyprexaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$14falsefalseUSDtruefalse{us-gaap_LossContingenciesByNatureOfContingencyAxis} : Marketing and Promotional Practices [Member] {us-gaap_ProductOrServiceAxis} : Zyprexa [Member] 4/1/2009 - 9/30/2009 USD ($) $Duration_4_1_2009_To_9_30_2009http://www.sec.gov/CIK0000059478duration2009-04-01T00:00:002009-09-30T00:00:00falsefalseMarketing and Promotional Practices [Member]us-gaap_LossContingenciesByNatureOfContingencyAxisxbrldihttp://xbrl.org/2006/xbrldilly_MarketingAndPromotionalPracticesMemberus-gaap_LossContingenciesByNatureOfContingencyAxisexplicitMemberfalsefalseZyprexa [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldilly_ZyprexaMemberus-gaap_ProductOrServiceAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false0lly_LossContingencyNumberOfClaimantsllyfalsenadurationThe number of claimants in a given litigation or loss contingencyfalsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8truefalsefalse3272032720falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:integerItemTypeintegerThe number of claimants in a given litigation or loss contingencyNo authoritative reference available.falsefalse3false0lly_LossContingencyNumberOfClaimsllyfalsenadurationThe number of claims in a particular litigation or loss contingency.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5truefalsefalse1800018000falsefalsefalsetruefalse6truefalsefalse80008000falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:integerItemTypeintegerThe number of claims in a particular litigation or loss contingency.No authoritative reference available.falsefalse4false0lly_LossContingencyNumberOfLawsuitsllyfalsenadurationNumber of lawsuits in a particular litigation or loss contingency.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7truefalsefalse7070falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9truefalsefalse5050falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:integerItemTypeintegerNumber of lawsuits in a particular litigation or loss contingency.No authoritative reference available.falsefalse5false0lly_LossContingencyNumberOfPlaintiffsllyfalsenadurationThe number of plantiffs pursuant to particular litigation or loss contingency.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7truefalsefalse150150falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9truefalsefalse5050falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:integerItemTypeintegerThe number of plantiffs pursuant to particular litigation or loss contingency.No authoritative reference available.falsefalse6false0lly_LossContingencyNumberOfStatesllyfalsenadurationNumber of states prusuant to a particular litigation or loss contingency.falsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1truefalsefalse3232falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10truefalsefalse3636falsefalsefalsetruefalse11truefalsefalse3232falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:integerItemTypeintegerNumber of states prusuant to a particular litigation or loss contingency.No authoritative reference available.falsefalse7false0us-gaap_ProductLiabilityAccrualPeriodExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalse2truefalsefalse00falsetruefalsefalsefalse3truefalsefalse230000000230.0falsetruefalsefalsefalse4truefalsefalse14770000001477.0falsetruefalsefalsefalse5truefalsefalse500000000500.0falsetruefalsetruefalse6truefalsefalse700000000700.0falsetruefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10truefalsefalse14200000001420.0falsetruefalsetruefalse11truefalsefalse6200000062.0falsetruefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13truefalsefalse1500000015.0falsetruefalsetruefalse14truefalsefalse230000000230.0falsetruefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of loss reported during the period pertaining to product liability.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 9 falsefalse8false0us-gaap_LossContingencySettlementAgreementTermsus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsefalsefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00<div class="MetaData"> <p class="MsoNormal" style="font-size: 10pt; margin: 0in 0in 0pt; font-family: 'Times New Roman','serif'; text-align: left;" align="left">While there was no finding that we violated any provision of the state laws under which the investigations were conducted, we paid $<font class="_mt">62.0</font>&nbsp;million and agreed to undertake certain commitments regarding Zyprexa for a period of six years, through consent decrees filed with the settling states.</p></div>While there was no finding that we violated any provision of the state laws under which the investigations were conducted, we paid $62.0&nbsp;million andfalsefalsefalsetruefalse12falsefalsefalse00<font class="_mt">As part of the settlement, we have entered into a corporate integrity agreement with the Office of Inspector General (OIG) of the U.S.&nbsp;Department of Health and Human Services (HHS), which requires us to maintain our compliance program and to undertake a set of defined corporate integrity obligations for five years.</font>As part of the settlement, we have entered into a corporate integrity agreement with the Office of Inspector General (OIG) of the U.S.&nbsp;Department offalsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringDescription of the terms of a settlement agreement which resolved the legal matter, including amount and timing of payment, and the nature of rights obtained or lost (such as patent, trademark, copyright, license and franchise rights).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 9, 10, 11, 12 falsefalse147Contingencies (Details) (USD $)HundredThousandsUnKnownUnKnownUnKnowntruetrue